Equities analysts predict that Asterias Biotherapeutics Inc (NYSE:AST) will post $1.43 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for Asterias Biotherapeutics’ earnings, with the lowest sales estimate coming in at $1.30 million and the highest estimate coming in at $1.50 million. Asterias Biotherapeutics reported sales of $2.08 million in the same quarter last year, which would suggest a negative year over year growth rate of 31.3%. The company is scheduled to issue its next quarterly earnings results on Monday, November 13th.

According to Zacks, analysts expect that Asterias Biotherapeutics will report full-year sales of $1.43 million for the current financial year, with estimates ranging from $3.70 million to $5.68 million. For the next financial year, analysts forecast that the firm will post sales of $3.50 million per share, with estimates ranging from $200,000.00 to $9.90 million. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Asterias Biotherapeutics.

Asterias Biotherapeutics (NYSE:AST) last issued its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.18) EPS for the quarter, hitting analysts’ consensus estimates of ($0.18). The firm had revenue of $0.32 million during the quarter, compared to analyst estimates of $1.25 million. Asterias Biotherapeutics had a negative return on equity of 86.25% and a negative net margin of 2,762.03%.

Several equities analysts have recently issued reports on AST shares. HC Wainwright set a $12.00 target price on shares of Asterias Biotherapeutics and gave the company a “buy” rating in a report on Monday, June 12th. Zacks Investment Research upgraded shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a report on Monday, July 17th.

Shares of Asterias Biotherapeutics (NYSE:AST) opened at 3.25 on Friday. Asterias Biotherapeutics has a one year low of $2.83 and a one year high of $5.80. The firm’s 50-day moving average price is $3.36 and its 200-day moving average price is $3.35. The company’s market capitalization is $162.43 million.

TRADEMARK VIOLATION WARNING: “Asterias Biotherapeutics Inc (AST) Expected to Post Quarterly Sales of $1.43 Million” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/08/asterias-biotherapeutics-inc-ast-expected-to-post-quarterly-sales-of-1-43-million.html.

Hedge funds have recently added to or reduced their stakes in the company. Family Management Corp lifted its holdings in shares of Asterias Biotherapeutics by 15.6% during the second quarter. Family Management Corp now owns 47,424 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 6,416 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Asterias Biotherapeutics by 4.6% during the second quarter. California State Teachers Retirement System now owns 47,764 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 2,100 shares during the last quarter. Teachers Advisors LLC raised its holdings in Asterias Biotherapeutics by 13.1% in the 2nd quarter. Teachers Advisors LLC now owns 58,028 shares of the biotechnology company’s stock worth $206,000 after acquiring an additional 6,714 shares during the last quarter. Finally, State Street Corp raised its holdings in Asterias Biotherapeutics by 24.1% in the 2nd quarter. State Street Corp now owns 328,717 shares of the biotechnology company’s stock worth $1,169,000 after acquiring an additional 63,773 shares during the last quarter.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Get a free copy of the Zacks research report on Asterias Biotherapeutics (AST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.